MX2021003288A - Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica. - Google Patents

Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.

Info

Publication number
MX2021003288A
MX2021003288A MX2021003288A MX2021003288A MX2021003288A MX 2021003288 A MX2021003288 A MX 2021003288A MX 2021003288 A MX2021003288 A MX 2021003288A MX 2021003288 A MX2021003288 A MX 2021003288A MX 2021003288 A MX2021003288 A MX 2021003288A
Authority
MX
Mexico
Prior art keywords
peripheral neuropathy
oxaliplatin
medication
malignant tumor
anticancer drug
Prior art date
Application number
MX2021003288A
Other languages
English (en)
Inventor
Takumi Sakai
Genichi KUSAKAWA
Yugo UCHIDA
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of MX2021003288A publication Critical patent/MX2021003288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un objetivo de la presente invención es proveer un medicamento eficaz y seguro que tenga un efecto de mitigación de afecciones y/o supresión del inicio de una neuropatía periférica inducida por la administración de un agente anti-tumor maligno, oxaliplatino, en un paciente humano con cáncer que recibe un tratamiento anti-tumor maligno con oxaliplatino. Se provee medicamento para mitigar afecciones y/o suprimir el inicio de una neuropatía periférica inducida por oxaliplatino en un tratamiento anti-tumor maligno, que consiste en la repetición de un ciclo individual que comprende la administración intravenosa de oxaliplatino a un paciente humano con cáncer y después el retiro del fármaco, que contiene como ingrediente activo trombomodulina para administrar por vía intravenosa 0.06 mg/kg de trombomodulina una vez cada dicho ciclo individual del tratamiento, el primer día de cada dicho ciclo.
MX2021003288A 2018-09-28 2019-09-27 Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica. MX2021003288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018183447 2018-09-28
PCT/JP2019/038066 WO2020067389A1 (ja) 2018-09-28 2019-09-27 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬

Publications (1)

Publication Number Publication Date
MX2021003288A true MX2021003288A (es) 2021-05-13

Family

ID=69950738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003288A MX2021003288A (es) 2018-09-28 2019-09-27 Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.

Country Status (12)

Country Link
EP (1) EP3858371A4 (es)
JP (1) JP7245844B2 (es)
KR (1) KR20210049143A (es)
CN (1) CN112839669A (es)
AU (1) AU2019347406B9 (es)
BR (1) BR112021001716A2 (es)
CA (1) CA3112679A1 (es)
IL (1) IL281818A (es)
MX (1) MX2021003288A (es)
TW (1) TWI739164B (es)
WO (1) WO2020067389A1 (es)
ZA (1) ZA202101882B (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
WO2008044631A1 (fr) * 2006-10-06 2008-04-17 Asahi Kasei Pharma Corporation Agent thérapeutique et/ou améliorant pour la coagulation intravasculaire disséminée
US8613962B2 (en) * 2007-08-31 2013-12-24 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
KR101672108B1 (ko) * 2011-11-15 2016-11-02 아사히 가세이 파마 가부시키가이샤 패혈증의 치료 및/또는 개선을 위한 의약
JP6124417B2 (ja) * 2012-05-31 2017-05-10 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Also Published As

Publication number Publication date
IL281818A (en) 2021-05-31
WO2020067389A1 (ja) 2020-04-02
TWI739164B (zh) 2021-09-11
CN112839669A (zh) 2021-05-25
AU2019347406A1 (en) 2021-04-29
CA3112679A1 (en) 2020-04-02
EP3858371A4 (en) 2022-07-20
EP3858371A1 (en) 2021-08-04
JPWO2020067389A1 (ja) 2021-08-30
AU2019347406B2 (en) 2023-10-19
TW202023537A (zh) 2020-07-01
BR112021001716A2 (pt) 2021-04-27
JP7245844B2 (ja) 2023-03-24
KR20210049143A (ko) 2021-05-04
ZA202101882B (en) 2022-09-28
AU2019347406B9 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP2015187125A5 (es)
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
EP4233861A3 (en) Compositions for treatment of essential tremor
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
RU2018121615A (ru) Модуляторы активности комплемента
MX2022006208A (es) Metodos de tratamiento del cancer de pulmon de celulas peque?as con formulaciones de lurbinectedina.
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
JP2016515586A5 (es)
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
JP2016505050A5 (es)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2021003288A (es) Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
BR112022013264A2 (pt) Combinação de formas de dosagem oral sólida de decitabina e cedazuridina
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
MX2019001210A (es) Composicion farmaceutica anticancer.
JP2020524167A5 (es)
MX2021008353A (es) Uso de nitazoxanida en el tratamiento de pacientes con covid-19.
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
WO2022186926A3 (en) Methods for inhibiting coronaviruses using sulforaphane
RU2021107897A (ru) Лекарственное средство для облегчения состояний и/или подавления возникновения периферической невропатии, вызванной агентом против злокачественной опухоли
IL310909A (en) Dosing regimens associated with delayed-release injectable formulations of paliperidone